Evidence map›Paper›PMID 40337340›Full record

ArticleERJ open research2025

Progression of interstitial lung disease after the Envisia Genomic Classifier.

Augustine Chung, Andrea Oh, Catherine Durant, Richard Watson, Jessica Channick, Greg Fishbein, Lila Pourzand, Sharon Kim, Reza Ronaghi, Scott Oh and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Augustine ChungDepartment of Medicine, Division of Pulmonary, Critical Care, Allergy, and Immunology, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA, USA.
Andrea OhDepartment of Radiologic Sciences, Division of Cardiothoracic Imaging, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA, USA.
Catherine DurantDepartment of Medicine, Division of Pulmonary, Critical Care, Allergy, and Immunology, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA, USA.
Richard WatsonDepartment of Medicine, Division of Pulmonary, Critical Care, Allergy, and Immunology, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA, USA.
Jessica ChannickDepartment of Medicine, Division of Pulmonary, Critical Care, Allergy, and Immunology, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA, USA.
Greg FishbeinDepartment of Anatomic Pathology, Division of Thoracic Pathology, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA, USA.ORCID https://orcid.org/0000-0002-3632-5654
Lila PourzandDepartment of Radiologic Sciences, Division of Cardiothoracic Imaging, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA, USA.
Sharon KimCollege of Letters and Sciences, University of California at Los Angeles, Los Angeles, CA, USA.
Reza RonaghiDepartment of Medicine, Division of Pulmonary, Critical Care, Allergy, and Immunology, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA, USA.
Scott OhDepartment of Medicine, Division of Pulmonary, Critical Care, Allergy, and Immunology, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA, USA.
Grace KimDepartment of Radiologic Sciences, Division of Cardiothoracic Imaging, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA, USA.ORCID https://orcid.org/0000-0003-1225-3489
S Sam WeigtDepartment of Medicine, Division of Pulmonary, Critical Care, Allergy, and Immunology, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA, USA.

Funding

UCLA Pulmonary and Critical Care Medicine Training ProgramT32HL072752 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JOHN A BELPERIO, TOMAS GANZ · 2003 to 2026
$8.3M
NHLBI NIH HHS T32 HL072752
6 · The paper itself

Abstract

Background: Interstitial lung disease (ILD) represents a heterogenous group of diseases that have substantial morbidity and mortality. The Envisia Genomic Classifier (EGC) is a test that analyses RNA derived from transbronchial biopsy (TBBx) samples to make a positive or negative genomic usual interstitial pneumonitis (UIP) designation. Our study assesses the ability for the EGC to predict progression of disease, with a longer duration of follow-up than previous studies. Methods: Patients referred for cryobiopsy for outpatient workup of ILD concurrently had TBBx and EGC testing performed. We performed a retrospective analysis to assess differences in progression of disease between EGC-positive and negative patients, applying Kaplan-Meier survival analysis and log-rank tests. Confidence in ILD diagnosis before and after the EGC result was also noted, and the difference in confidence levels was assessed by a Wilcoxon signed-rank test. Results: 82 patient cases were analysed. EGC-positive patients had a shorter progression-free survival (PFS) than EGC-negative patients, (p<0.0001), with 622 Conclusion: EGC positivity predicts worse ILD progression over a sustained follow-up period. The ability to predict worse prediction early in the ILD course without the need for surgical biopsy would have significant clinical impact.

Identifiers

PMID40337340
PMCPMC12053734

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.